Table 1 Histomorphometric results in rats treated with glucocorticoids (GC) and risedronate (Ris)
From: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
| Â | Controls | Ris | GC | GC+Ris |
|---|---|---|---|---|
Bone volume/tissue volume (%) | 35 ± 1 | 39 ± 1(b,c) | 31 ± 1(b) | 36 ± 1(a) |
Trabecular thickness (μm) | 50 ± 1 | 55 ± 1(b) | 43 ± 1(b) | 53 ± 1(a) |
Trabecular number (N/mm) | 3.4 ± 0.2 | 4.6 ± 0.1(b) | 2.9 ± 0.1(b) | 4.4 ± 0.1(a,b) |
Trabecular separation (μm) | 155 ± 6.5 | 139 ± 4.8(b,c) | 273 ± 5.3(b) | 144 ± 6.1(a) |
Mineral apposition rate (μm/day) | 0.66 ± 0.04 | 0.65 ± 0.04 | 0.62 ± 0.05(b) | 0.65 ± 0.04 |
Mineralized surface/BS (%) | 11.2 ± 1.5 | 9.8 ± 0.9(b) | 9.6 ± 0.9(b) | 9.8 ± 1.0(b) |
Bone formation rate/BS (μm3/μm2/day | 7.4 ± 1.2 | 6.3 ± 0.6(b) | 5.9 ± 0.6(b) | 6.3 ± 0.6(b) |
Wall thickness (μm) | 16.8 ± 1.3 | 24.9 ± 3.6(b) | 12.0 ± 3.1(b) | 22.8 ± 5.9(a,b) |
Activation frequency (N/yr) | 1.6 ± 0.3 | 0.9 ± 0.2(b) | 1.9 ± 0.6 | 1.0 ± 0.3(a,b) |
Active formation period (days) | 25.4 ± 2.0 | 38.8 ± 5.4(b) | 19.4 ± 4.8 | 35.3 ± 9.3(a,b) |
Eroded surface/BS (%) | 1.9 ± 1.0 | 1.7 ± 0.7 | 2.2 ± 1.1 | 1.9 ± 1.1 |